RecruitingLiver FibrosisHepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
Sponsor: AstraZeneca
Where it's recruiting
Arizona
Chandler · Tucson
California
Fresno
Florida
Jupiter · Miami · Port Orange
Missouri
Kansas City · St Louis
Nevada
Las Vegas
North Carolina
Morehead City · Raleigh
Ohio
Westlake
Oklahoma
Yukon
Tennessee
Clarksville
Texas
Austin · Denison · Georgetown · Houston …
Source: ClinicalTrials.gov · NCT07610837 · last updated 2026-11-03